The phase 2 trial “Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer” (NCT05385185) is combining the use of ICIs with recombinant endostatin, an anti-angiogenic factor in patients with LMD from lung cancer. Here, COL18A1 is linked to lung cancer.